目的 探討注射用丹參多酚酸治療腦梗死急性期患者的療效及對(duì)同型半胱氨酸（Hcy）、D-二聚體和超敏C反應(yīng)蛋白（hs-CRP）水平影響。方法 選擇2016年1月—2019年1月于安陽市第六人民醫(yī)院收治的腦梗死急性期患者102例，隨機(jī)分為對(duì)照組51例與治療組51例。對(duì)照組患者常規(guī)治療，治療組在對(duì)照組基礎(chǔ)上聯(lián)用注射用丹參多酚酸（100 mg+250 mL的0.9%氯化鈉溶液中，靜脈滴注，1次/d）。兩組療程均為2周，比較兩組療效，治療前后日常生活活動(dòng)能力指數(shù)（Balthel指數(shù)）評(píng)分、蒙特利爾認(rèn)知評(píng)估量表（MoCA）評(píng)分和神經(jīng)功能缺損程度評(píng)分（NIHSS評(píng)分）變化，血清Hcy、D-二聚體和hs-CRP水平變化及不良反應(yīng)。結(jié)果 治療組治療總有效率（92.16%）高于對(duì)照組（70.59%）（P<0.05）。治療后，兩組Balthel指數(shù)評(píng)分和MoCA評(píng)分較治療前升高，而NIHSS評(píng)分較治療前降低（P<0.05）；治療組Balthel指數(shù)評(píng)分和MoCA評(píng)分高于對(duì)照組，而NIHSS評(píng)分低于對(duì)照組（P<0.05）。治療后，兩組血清Hcy、D-二聚體和hs-CRP水平較治療前降低（P<0.05）；且治療組血清Hcy、D-二聚體和hs-CRP水平低于對(duì)照組（P<0.05）。結(jié)論 注射用丹參多酚酸治療腦梗死急性期患者療效良好，可降低Hcy、D-二聚體和hs-CRP水平，值得臨床借鑒。

Objective To investigate the therapeutic effect of Salvianolic Acids for Injection (SAFI) on acute cerebral infarction patients and its effects on the levels of homocysteine (Hcy), D-dimer and hypersensitive C-reactive protein (hs-CRP). Methods The 102 patients with acute cerebral infarction admitted to our hospital from January 2016 to January 2019 were divided into control group (51 cases) and treatment group (51 cases) according to random number table method. The control group received routine treatment, while the treatment group received intravenous drip of SAFI 100 mg+250 mL 0.9% sodium chloride solution once a day on the basis of the control group. Both groups were treated for 2 weeks. The therapeutic effects, the changes of Balthel index, Montreal Cognitive Assessment Scale (MoCA) and Neurological Deficiency Scale (NIHSS) before and after treatment, the changes of serum Hcy, D-dimer and hs-CRP levels, and the adverse reactions were compared between the two groups. Results The total effective rate of the treatment group (92.16%) was higher than that of the control group (70.59%) (P<0.05). After treatment, the Balthel index score and MoCA score of the two groups were higher than those before treatment, while the NIHSS score was lower than before treatment (P<0.05); after treatment, the Balthel index score and MoCA score of the treatment group were higher than those of the control group, while the NIHSS score was lower than that of the control group (P<0.05). After treatment, the levels of serum Hcy, D-dimer and hs-CRP in the two groups were lower than those before treatment (P<0.05); after treatment, the levels of serum Hcy, D-dimer and hs-CRP in the treatment group were lower than those in the control group (P<0.05). Conclusion SAFI is effective in the treatment of acute cerebral infarction. It can reduce the levels of Hcy, D-dimer and hs-CRP, which is worthy of clinical reference.

R969.4